





FIG. 1

**FIG. 2**






FIG. 2
(CONT.)

AFFINITY AND POTENCY OF COMPETITIVE BINDING VPAC BY VIP-DERIVED
NOVEL PEPTIDES CORRELATED WITH INCREASING SURVIVAL IN
MICE WITH C1498 MYELOID LEUKEMIA



NEGATIVE LOG OF BINDING AFFINITY OF PEPTIDE TO HUMAN VIP RECEPTOR

FIG. 3










FIG. 6

**FIG. 7**



GROWTH RATE: TUMOR VOLUME (MM³)**FIG. 9**

SUBSTITUTE SHEET (RULE 26)




FIG. 10C

FIG. 10B






FIG. 10A








FIG. 11

FIG. 12





15/65




FIG. 14C




FIG. 14A

TUMORS FROM SCRAM+ISO IgG TREATED




FIG. 14B




FIG. 15




FIG. 16A




FIG. 16B






FIG. 16D

FIG. 16C




FIG. 16G




FIG. 16F




FIG. 17A




FIG. 17D




FIG. 17E




FIG. 17C




FIG. 17G




FIG. 17I




FIG. 17H




FIG. 18A




FIG. 18B





FIG. 18C

FIG. 18D

FIG. 18E






FIG. 19G




FIG. 19H




FIG. 19I

SHARED CLONES IN Scram+IgG	SHARED CLONES IN ANT008+ IgG	SHARED CLONES IN Scram+aPD-1	SHARED CLONES IN ANT008+ aPD-1
CASSLEGTGGYEQYF CASSLRDNQAPLF CASSQDEAGGFAETLYF CASSDTGGQDTQYF CASSDAGYEQYF CASSDGGHEQYF	CASSLEGTGGYEQYF CASSDAGYEQYF CASSPDSYEQYF CASSGQGNYAEQFF CASSQDRQDEQYF CASSEAGYEQYF	CASSPDSYEQYF CASSLEGTGGYEQYF CASSLRGGSYEQYF CTCSAEGTPNSDYTF CASRDSAETLYF CASSLRDNQAPLF CASSGQGNYAEQFF CASSPQGNYAEQFF	CASSDAGYEQYF CASSLEGTGGYEQYF CASSDWGSSYEQYF CASSWGQDTQYF CASSLEGS AETLYF CASSDAAETLYF CASSPRNTGQLYF CASRDSAETLYF CASSQDEAGGFAETLYF CASSLRDNQAPLF CASSLEYEQYF CASSPDSYEQYF

FIG. 20B




FIG. 20A




FIG. 20C

28/65




FIG. 20D




FIG. 20E




FIG. 20G




FIG. 20F




FIG. 21A




FIG. 21B




FIG. 21C




FIG. 21E




FIG. 21F

FIG. 21G

FIG. 21H

FIG. 21I




FIG. 22B








FIG. 22A

33/65

**FIG. 22C****FIG. 22D**






FIG. 23A




FIG. 23B




FIG. 23C




FIG. 23D




FIG. 24A




FIG. 24B




FIG. 24C

MUS MUSCULUS VASOACTIVE INTESTINAL PEPTIDE RECEPTOR 2 (VIPR2), mRNA

SEQUENCE ID: [NM_009511.2](#) LENGTH: **3403** NUMBER OF MATCHES: **1**

RANGE 1: 168 TO 268 [GENBANK](#) [GRAPHICS](#)

		▽	NEXT MATCH	△	PREVIOUS MATCH
SCORE					
180 BITS(97)					STRAND
			GAPS		PLUS/PLUS
			1/101(0%)		
QUERY	49	GGTGAGCAGCATCCACAAATGTCGCTTTCATCTAGAAATACAAGAAGAGACAAA		108	
SBJCT	168	GGTGAGCAGCATCCACAAATGTCGCTTTCATCTAGAAATACAAGAAGAGACAAA		227	
QUERY	109	ATGTGCAGAGCTGCTAAGCAGCCAAAG - GAGAAATCAGAGAG		148	
SBJCT	228	ATGTGCAGAGCTGCTAAGCAGCCAAACGGAGAATCAGAGAG		268	

FIG. 24D




FIG. 24E




FIG. 24F




FIG. 24G





FIG. 24H



SUBSTITUTE SHEET (RULE 26)

FIG. 25B




FIG. 25C




FIG. 26A




FIG. 26B




FIG. 26C




FIG. 26D




FIG. 27A






FIG. 27B

**FIG. 27C****FIG. 27D**




FIG. 28C




FIG. 28B




FIG. 28A




FIG. 28E




FIG. 28D




FIG. 29B




FIG. 29A




FIG. 29D




FIG. 29C




FIG. 29G




FIG. 29F







FIG. 29E

**FIG. 30A****FIG. 30B**


52/65

MASSON'S TRICHROME

SCRAM+IgG



ANT008+IgG



SCRAM+aPD-1








FIG. 30C

SUBSTITUTE SHEET (RULE 26)






FIG. 31A

A

B




FIG. 31B




FIG. 31C





FIG. 32

ANT308 IN COMBINATION WITH ANTI-PD-1 REDUCED HEPATIC METASTASES
FROM INTRAOCULAR MELANOMA MICE IN 2 WEEKS (N=4)
COMPARED TO THE CONTROL: * $P<0.05$, ** $P<0.01$ (T-TEST)
HEPATIC METASTASES IN 2 WEEKS AFTER ANT308/ANTI-PD-1



HEPATIC METASTASES IN 3 WEEKS AFTER ANT308/ANTI-PD-1				
	CONTROL	ANTI-PD-1	ANT308	ANT308+ANTI-PD-1
NUMBER OF HEPATIC METASTASES	91	45	29	32
	96	62	58	23
	43	77	28	26
	55	34	36	47
AVG	71.25	54.5	37.75	32
SD	22.71976	16.37834	12.09080229	9.246621004
T-TEST: CONTROL		0.340205	0.065036254	0.032358294
T-TEST: ANTI-PD-1			0.204006601	0.083652757
T-TEST: ANT308				0.537175769
ONE-TAILED DISTRIBUTION		0.170102		





FIG. 33
SUBSTITUTE SHEET (RULE 26)

59/65


ANT308 ALONE OR COMBINED WITH ANTI-PD-1 DECREASED HEPATIC METASTASES FROM INTRAOCULAR MELANOMA MICE IN 3 WEEKS (N=6)
COMPARED TO THE CONTROL: * $P<0.05$, ** $P<0.01$
COMPARED TO THE CONTROL: # $P<0.05$, ## $P<0.01$ (T-TEST)



HEPATIC METASTASES IN 3 WEEKS AFTER ANT308/ANTI-PD-1				
	CONTROL	ANTI-PD-1	ANT308	ANTI308+ ANTI-PD-1
NUMBER OF HEPATIC METASTASES	104	64	19	30
	79	85	28	18
	74	37	15	13
	71	90	17	16
	69	41	19	25
	85	44	23	21
AVG	80.33333	60.16667	20.16666667	20.5
SD	11.82746	21.16142	4.258977446	5.6789083406
T-TEST: CONTROL		0.092495	8.5047E-07	1.32845E-06
T-TEST: ANTI-PD-1			0.002000317	0.002330202
T-TEST: ANT308				0.918450727
ONE-TAILED DISTRIBUTION		0.046248		

FIG. 34

HEPATIC METASTASES IN 2 AND 3 WEEKS AFTER ANT308/ANTI-PD-1 (N=10)
COMPARED TO THE CONTROL: * $P<0.05$, ** $P<0.01$
COMPARED TO ANTI-PD-1: # $P<0.05$, ## $P<0.01$ (T-TEST)





SUBSTITUTE SHEET (RULE 26)

HEPATIC METASTASES IN 2 AND 3 WEEKS AFTER ANT308/ANTI-PD-1					
	CONTROL	ANTI-PD-1	ANT308	ANTI308+ANTI-PD-1	
	104	64	19	30	
	79	85	28	18	
	74	37	15	13	
	71	90	17	16	
	69	41	19	25	
	85	44	23	21	
	91	45	29	32	
	96	62	58	23	
	43	77	28	26	
	55	34	36	47	
AVG	76.7	57.9	27.2	25.1	
SD	17.61278	19.58801	11.98165264	9.235259	
T-TEST: CONTROL		0.046205	1.64162E-06	3.61E-07	
T-TEST: ANTI-PD-1			0.000819527	0.000252	
T-TEST: ANT308				0.682003	

FIG. 35

ANT308 SUPPRESSED GROWTH OF LIVER METASTASES IN
3 WEEKS AFTER TUMOR INOCULATION (N=6)
COMPARED TO THE CONTROL: * P<0.05, ** P<0.01 (CHI-SQUARED TEST)



3 WEEKS: THE NUMBER OF MICE WITH LIVER METASTASES GREATER THAN 100 MICRONS IN DIAMETER				
	CONTROL	ANTI-PD-1	ANT308	ANT308+ ANTI-PD-1
WITH LARGER METASTASES	4	3	1	1
WITHOUT LARGER METASTASES	2	3	5	5
CHI-SQUARE DISTRIBUTION: CONTROL		0.386476	0.009374768	0.009374768
CHI-SQUARE DISTRIBUTION: ANTI-PD-1			0.196795602	0.102470435
CHI-SQUARE DISTRIBUTION: ANT308			1	1

FIG. 36

ANT308 INHIBITED ANGIOGENESIS (ARROW) AND GROWTH OF LIVER METASTASES (N=10)
COMPARED TO THE CONTROL: * $P<0.05$, ** $P<0.01$ (CHI-SQUARED TEST)




FIG. 37

THE SIZE OF INTRAOCULAR MELANOMA WAS NOT AFFECTED BY EITHER ANT308 ALONE OR COMBINED ANTI-PD-1
(ANT308/ANTI-PD-1 MAY NOT PENETRATE INTO THE EYE DUE TO THE BLOOD-OCULAR BARRIER?)




FIG. 38




FIG. 39




FIG. 40